Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:MLYS NASDAQ:MRUS NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$39.47+2.2%$31.95$16.50▼$43.58$3.44BN/A47,381 shs4,896 shsMLYSMineralys Therapeutics$14.38+0.4%$14.91$8.24▼$18.38$936.64M-0.3558,495 shs553,958 shsMRUSMerus$60.95+7.8%$51.66$33.19▼$62.98$4.21B1731,351 shs903,112 shsRAREUltragenyx Pharmaceutical$27.85+2.0%$36.00$26.85▼$60.37$2.64B0.26958,448 shs1.26 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+5.06%-7.76%+20.20%+106.30%+3,861,999,900.00%MLYSMineralys Therapeutics-2.05%-0.35%+6.47%+7.27%-1.78%MRUSMerus+2.76%+3.67%+6.02%+31.24%-3.96%RAREUltragenyx Pharmaceutical+0.40%-34.10%-26.41%-23.48%-39.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AMLYSMineralys Therapeutics2.1958 of 5 stars3.41.00.00.01.94.20.0MRUSMerus1.929 of 5 stars3.61.00.00.02.12.50.0RAREUltragenyx Pharmaceutical4.4617 of 5 stars4.51.00.03.82.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AMLYSMineralys Therapeutics 2.75Moderate Buy$32.25124.35% UpsideMRUSMerus 3.14Buy$84.6438.87% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$83.64200.39% UpsideCurrent Analyst Ratings BreakdownLatest MLYS, RARE, AAPG, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$88.00 ➝ $65.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.006/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.005/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M3.51N/AN/A$0.48 per share82.23MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/AMRUSMerus$36.13M116.75N/AN/A$9.46 per share6.44RAREUltragenyx Pharmaceutical$560.23M4.70N/AN/A$2.76 per share10.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AMLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest MLYS, RARE, AAPG, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78N/AN/AN/AN/AN/A8/7/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A8/7/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/AN/AN/A5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26MLYSMineralys TherapeuticsN/A26.4826.48MRUSMerusN/A5.865.86RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AMLYSMineralys Therapeutics84.46%MRUSMerus96.14%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AMLYSMineralys Therapeutics25.56%MRUSMerus4.57%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/AMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableMLYS, RARE, AAPG, and MRUS HeadlinesRecent News About These CompaniesBank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE)4 hours ago | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREJuly 17 at 10:00 AM | prnewswire.comWedbush Equities Analysts Reduce Earnings Estimates for RAREJuly 17 at 7:16 AM | marketbeat.comWilliam Blair Issues Negative Forecast for RARE EarningsJuly 17 at 4:54 AM | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Lowered by Bank of New York Mellon CorpJuly 17 at 3:32 AM | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 5.7% on Analyst DowngradeJuly 17 at 2:27 AM | americanbankingnews.comFDA rejects Ultragenyx gene therapy over manufacturing concernsJuly 16 at 8:33 PM | biopharmadive.comBWilliam Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)July 16 at 10:43 AM | insidermonkey.comFY2025 EPS Estimates for RARE Cut by Cantor FitzgeraldJuly 16 at 6:46 AM | marketbeat.comWilliam Blair Has Bearish Estimate for RARE FY2025 EarningsJuly 16 at 6:46 AM | marketbeat.comWedbush Analysts Decrease Earnings Estimates for RAREJuly 16 at 6:25 AM | marketbeat.comMorgan Stanley Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceJuly 16 at 4:09 AM | americanbankingnews.comUltragenyx hit again, this time with a CRL in rare diseaseJuly 15 at 10:19 PM | bioworld.comBUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAJuly 15 at 10:19 PM | msn.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Down 5.7% on Analyst DowngradeJuly 15 at 11:57 AM | marketbeat.comUltragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAJuly 15 at 9:31 AM | zacks.comQ4 EPS Forecast for Ultragenyx Pharmaceutical Cut by AnalystJuly 15 at 8:23 AM | marketbeat.comUltragenyx: The High Stakes Of Binary Events And A Short Cash RunwayJuly 15 at 6:55 AM | seekingalpha.comUltragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionJuly 14 at 10:14 AM | investors.comWedbush Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock PriceJuly 14 at 9:32 AM | marketbeat.comUltragenyx receives CRL from US FDA for UX111 AAV gene therapy to treat Sanfilippo syndrome type AJuly 14 at 9:27 AM | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Why Qualcomm’s Latest Price Target Can't Be IgnoredBy Sam Quirke | June 24, 2025View Why Qualcomm’s Latest Price Target Can't Be IgnoredMP Materials Stock Booms on New Government PositioningBy Gabriel Osorio-Mazilli | July 14, 2025View MP Materials Stock Booms on New Government PositioningTop 5 Undervalued Dividend Stocks With Strong Payout PotentialBy Ryan Hasson | July 7, 2025View Top 5 Undervalued Dividend Stocks With Strong Payout PotentialMLYS, RARE, AAPG, and MRUS Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$39.47 +0.85 (+2.20%) As of 02:35 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Mineralys Therapeutics NASDAQ:MLYS$14.38 +0.06 (+0.38%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Merus NASDAQ:MRUS$60.94 +4.44 (+7.85%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Ultragenyx Pharmaceutical NASDAQ:RARE$27.84 +0.54 (+1.96%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
